From Single Agents to Synergy: Redefining Therapeutic Strategies in MASLD
The recent approvals of resmetirom and semaglutide have marked a pivotal advance in the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Nevertheless, the modest fibrosis responses observed with current monotherapies and the persistence of substantial residual disease burden highlight the...